Article (Scientific journals)
MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.
Halkein, Julie; Tabruyn, Sebastien P.; Ricke-Hoch, Melanie et al.
2013In Journal of Clinical Investigation, 123 (5), p. 2143-54
Peer Reviewed verified by ORBi
 

Files


Full Text
halkein_tabruyn_hoch_JCI2013.pdf
Publisher postprint (4.55 MB)
Download
Annexes
halkein rev2 suppl figure+legendes final.pdf
Publisher postprint (984.51 kB)
suppl figures
Download
Halkein JCI rev2_Supplementary data.pdf
Publisher postprint (227.88 kB)
suppl data
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Peripartum cardiomyopathy (PPCM) is a life-threatening pregnancy-associated cardiomyopathy in previously healthy women. Although PPCM is driven in part by the 16-kDa N-terminal prolactin fragment (16K PRL), the underlying molecular mechanisms are poorly understood. We found that 16K PRL induced microRNA-146a (miR-146a) expression in ECs, which attenuated angiogenesis through downregulation of NRAS. 16K PRL stimulated the release of miR-146a-loaded exosomes from ECs. The exosomes were absorbed by cardiomyocytes, increasing miR-146a levels, which resulted in a subsequent decrease in metabolic activity and decreased expression of Erbb4, Notch1, and Irak1. Mice with cardiomyocyte-restricted Stat3 knockout (CKO mice) exhibited a PPCM-like phenotype and displayed increased cardiac miR-146a expression with coincident downregulation of Erbb4, Nras, Notch1, and Irak1. Blocking miR-146a with locked nucleic acids or antago-miRs attenuated PPCM in CKO mice without interrupting full-length prolactin signaling, as indicated by normal nursing activities. Finally, miR-146a was elevated in the plasma and hearts of PPCM patients, but not in patients with dilated cardiomyopathy. These results demonstrate that miR-146a is a downstream-mediator of 16K PRL that could potentially serve as a biomarker and therapeutic target for PPCM.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Halkein, Julie ;  Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Tabruyn, Sebastien P.
Ricke-Hoch, Melanie
Haghikia, Arash
Nguyen, Ngoc-Quynh-Nhu
Scherr, Michaela
Castermans, Karolien
Malvaux, Ludovic
Lambert, Vincent  ;  Centre Hospitalier Universitaire de Liège - CHU > Ophtalmologie
Thiry, Marc  ;  Université de Liège - ULiège > Département des sciences de la vie > Biologie cellulaire
Sliwa, Karen
Noël, Agnès ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Martial, Joseph ;  Université de Liège - ULiège > Département des sciences de la vie > Département des sciences de la vie
Hilfiker-Kleiner, Denise
Struman, Ingrid  ;  Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
More authors (5 more) Less
Language :
English
Title :
MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.
Publication date :
2013
Journal title :
Journal of Clinical Investigation
ISSN :
0021-9738
eISSN :
1558-8238
Publisher :
American Society for Clinical Investigation, United States - Michigan
Volume :
123
Issue :
5
Pages :
2143-54
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 14 May 2013

Statistics


Number of views
297 (41 by ULiège)
Number of downloads
669 (16 by ULiège)

Scopus citations®
 
378
Scopus citations®
without self-citations
332
OpenCitations
 
324

Bibliography


Similar publications



Contact ORBi